心玮医疗-B(06609.HK)发布公告，本集团预期截至2025年6月30日止6个月取得股东应占净利润不少于人 民币4000万元，较截至2024年6月30日止6个月(相应期间)取得的股东应占净亏损约人民币510万元大幅 转亏为盈。预期取得利润及业绩改善乃主要由于本集团的业务增长，导致与相应期间相比的收益增加及 本集团整体开支比率下降。 ...

董事会建议根据本公司组织章程细则、相关法律及法规利用本公司资本储备抵销其亏损。有关亏损抵销 须经股东以普通决议案方式批准，而相关建议将提呈本公司将于2025年8月29日举行的2025年第二次临 时股东大会供股东审议及通过为普通决议案。 心玮医疗-B(06609)发布公告，本集团预期截至2025年6月30日止6个月取得股东应占净利润不少于人民 币4000万元，较截至2024年6月30日止6个月(相应期间)取得的股东应占净亏损约人民币510万元大幅转 亏为盈。预期取得利润及业绩改善乃主要由于本集团的业务增长，导致与相应期间相比的收益增加及本 集团整体开支比率下降。 ...

董事会建议根据本公司组织章程细则、相关法律及法规利用本公司资本储备抵销其亏损。有关亏损抵销 须经股东以普通决议案方式批准，而相关建议将提呈本公司将于2025年8月29日举行的2025年第二次临 时股东大会供股东审议及通过为普通决议案。 智通财经APP讯，心玮医疗-B(06609)发布公告，本集团预期截至2025年6月30日止6个月取得股东应占净 利润不少于人民币4000万元，较截至2024年6月30日止6个月(相应期间)取得的股东应占净亏损约人民币 510万元大幅转亏为盈。预期取得利润及业绩改善乃主要由于本集团的业务增长，导致与相应期间相比 的收益增加及本集团整体开支比率下降。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容所產生或 因依賴該等內容而引致的任何損失承擔任何責任。 （股份代號：6609） 正面盈利預告 及建議利用資本儲備抵銷虧損 本公告由上海心瑋醫療科技股份有限公司（「本公司」，連同其附屬公司統稱「本 集團」）根據香港聯合交易所有限公司證券上市規則（「上市規則」）第13.09(2)條 以及香港法例第571章證券及期貨條例第XIVA部項下的內幕消息條文（定義見 上市規則）刊發。 Shanghai HeartCare Medical Technology Corporation Limited 上 海 心 瑋 醫 療 科 技 股 份 有 限 公 司 （ 於 中 華 人 民 共 和 國 註 冊 成 立 的 股 份 有 限 公 司 ） 董事長 王國輝 正面盈利預告 本公司董事會（「董事會」）欣然通知本公司股東（「股東」）及潛在投資者，根據 對本集團截至2025年6月30日止六個月（「報告期間」）之未經審核綜合管理賬目 之初步評估及董事會現時可得資料，本集團預期錄得股東應佔 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容所產生或 因依賴該等內容而引致的任何損失承擔任何責任。 (I)僱員代表監事變動； 及 (II)委任監事委員會主席 僱員代表監事變動 上海心瑋醫療科技股份有限公司（「本公司」，連同其附屬公司統稱「本集團」） 於2025年7月25日舉行僱員代表會議，並選舉劉紅寶先生（「劉先生」）為本公司 第二屆監事委員會（「監事委員會」）之僱員代表監事（「僱員代表監事」）。委任 劉先生為僱員代表監事將由2025年7月25日起生效，其任期將與第二屆監事委 員會的任期一致，彼於任期內不得就擔任僱員代表監事收取任何薪酬。 於同日，劉柏巍先生因個人工作安排而辭任本公司監事，並不再履行僱員代 表監事及監事委員會主席職務，彼已確認，彼與本公司董事（「董事」）會（「董事 會」）、監事委員會或本公司概無意見分歧，亦無有關其辭任之其他事宜須敦請 本公司股東（「股東」）或香港聯合交易所有限公司（「聯交所」）垂注，亦無彼針 對本集團的現有或待決訴訟或申索。本公司謹藉此機會感謝劉柏巍先生於擔 任本公司 ...

Summary of the Conference Call for Xinwei Medical Industry and Company Overview - The conference call discusses Xinwei Medical's focus on **interventional brain-machine interfaces (BMIs)**, leveraging its existing technology in the **neurovascular field**. The company aims to address complex issues such as paralysis through advanced medical devices [2][5]. Key Points and Arguments 1. **Product Development Timeline**: - Xinwei Medical plans to complete product optimization by **2025**, conduct preclinical tests and animal experiments in **2026**, and initiate non-blind clinical trials by the end of **2026** to early **2027**. The entire process to finalize reports is expected to take **two to three years** [2][10]. 2. **Market Potential**: - Approximately **1.5 to 2 million** new stroke patients are reported annually in China, with a cumulative patient population exceeding **30 million**. This presents a significant demand for rehabilitation solutions [4][18]. 3. **Technical Advantages**: - The interventional approach offers a signal acquisition strength comparable to semi-invasive methods while maintaining lower infection risks and higher safety [3][5]. The existing technology from Xinwei Medical's thrombectomy stents facilitates easier entry into this market [5]. 4. **Clinical Trial Costs**: - The estimated cost for clinical trials is around **200,000 to 300,000 RMB** per patient, with a minimum of **100 patients** required for trials [12][13]. 5. **Regulatory and Reimbursement Landscape**: - Currently, there are no clear regulations for interventional BMIs in the national medical insurance directory. However, future alignment with interventional methods is anticipated as technology matures [14]. 6. **Commercialization Strategy**: - The product will be marketed through hospitals, requiring inclusion in reimbursement directories. The pricing strategy will consider production costs and potential reimbursement to alleviate patient financial burdens [15][19]. 7. **Competitive Landscape**: - Domestic competitors include **Zhonghua Brain Machine**, while international players like **Zenko** have initiated small-scale clinical studies. However, most companies are still in early development stages [2][7]. 8. **Technical Barriers**: - Significant challenges exist in hardware design, particularly for the electrode stent and subcutaneous signal transmission systems. Xinwei Medical's experience over the past nine years provides a competitive edge in overcoming these barriers [8][9]. 9. **Future Adaptations**: - The initial focus is on stroke patients, but there is potential for expanding indications based on technological advancements and market needs [16][17]. 10. **Surgical Considerations**: - The surgical procedure is complex, positioned between interventional and surgical methods, with neurosurgery being the most suitable field for these operations [21]. Additional Important Insights - The current prototype has a high domestic production rate, with core components being locally sourced, indicating a robust domestic supply chain [11]. - The industry is still in its nascent stages, with significant time required for product validation and market introduction, potentially taking **3 to 5 years** for mature products to emerge [25][26]. - The impact of national medical insurance policies on neuro-interventional products is evolving, with a focus on maintaining competitive pricing while ensuring quality care [27].

（股份代號：6609） 就2025年第二次臨時股東大會暫停辦理H股過戶登記 上海心瑋醫療科技股份有限公司（「本公司」）董事會謹此宣佈，為釐定有權出 席將於2025年8月29日（星期五）舉行的2025年第二次臨時股東大會（「臨時股東 大會」）並於會上投票的本公司H股（「H股」）持有人清單，本公司將於2025年7月 30日（星期三）至2025年8月29日（星期五）（包括首尾兩日）暫停辦理H股過戶登 記。於2025年8月29日（星期五）名列本公司H股股東名冊的H股股東將有權出席 臨時股東大會並於會上投票。於該期間內概不會登記任何股份轉讓。為符合資 格出席臨時股東大會並於會上投票，所有H股轉讓文件連同相關股票必須不遲 於2025年7月29日（星期二）下午四時三十分送達本公司的香港H股股份過戶登記 處香港中央證券登記有限公司，地址為香港灣仔皇后大道東183號合和中心17 樓1712–1716號舖，以作登記。一份載有擬於臨時股東大會提呈的決議案詳情 之通函，連同該大會的通告，將適時寄發予本公司股東。 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示， ...

Market Overview - The Hang Seng Index fell by 0.45%, down 107 points, closing at 23,808 points, while the Hang Seng Tech Index decreased by 0.15% [1] - Early trading volume in Hong Kong stocks reached HKD 109.5 billion [1] Stablecoin Regulation - The Hong Kong Monetary Authority plans to release guidelines for stablecoin regulations this month, aiming to issue licenses within the year [1] - Stocks related to stablecoins saw significant gains, with Guotai Junan International rising by 8.2%, ZhongAn Online increasing by 5.64%, and Yike rising over 9% [1] New Tea Beverage Market - A subsidy war in the takeaway market has ignited the new tea beverage sector, with Guming and Cha Baidao both rising over 9% [1] Digital Health Services - Health Road saw its stock rise over 9% as its controlling shareholder voluntarily extended the lock-up period, focusing on a digital health service platform [1] Gaming Industry - Morgan Stanley reported that Macau's gaming revenue in June increased by 19% year-on-year to MOP 21.1 billion, exceeding analyst predictions by 9% [1] - Gaming stocks continued their upward trend, with Amax Holdings up 3.7%, Melco International Development up 1.6%, and MGM China up 2.1% [1] Medical Device Sector - In response to China's reciprocal restrictions on EU medical devices, the National Medical Products Administration issued support for high-end medical devices [1] - Medical device stocks experienced broad gains, with Spring Medical up 1.86%, Yongsheng Medical up 7.27%, and Xinwei Medical-B up 5.5% [1] Company Developments - China Rare Earth Holdings plans to spin off its gold business for independent listing on the Hong Kong Stock Exchange, potentially seeking financing before the spin-off [2] - Jihong Co. saw its stock rise over 10%, with a projected over 55% year-on-year increase in net profit attributable to shareholders for the first half of the year [3] - H&H International Holdings is expected to see a decline in net profit by 45% to 65% for the first half of the year, resulting in a drop of over 6% in its stock price [4]

Market Overview - The US stock market was closed on July 4th for Independence Day [1] Hong Kong Stock Market Highlights - Yum China (09987) rose over 3% after announcing the establishment of an innovation fund to convert operational needs into practical applications [2] - H&H International Holdings (01112) fell over 7%, expecting a 45% to 65% decline in net profit for the first half of the year [2] - China Rare Earth Holdings (03788) surged nearly 9% as it plans to spin off its gold business for independent listing on the Hong Kong Stock Exchange, potentially seeking financing before the spin-off [2] - Health Road (02587) jumped over 18% as its controlling shareholder voluntarily extended the lock-up period, focusing on digital health services [2] - Smoore International (06969) increased over 5% with the launch of Glo Hilo in Japan, maintaining high profit margins [2] - Tencent Music (01698) rose nearly 3% as institutions noted that recent acquisition plans would enhance overall content supply [2] - Jihong Co., Ltd. (02603) surged over 7%, with a projected net profit increase of over 55% year-on-year for the first half [2] - Solar stocks collectively declined, with Xinyi Solar (00968) down 4.86%, Fuyao Glass (06865) down 3.88%, New Energy (01799) down 3.19%, and Xinyi Glass (00868) down 2.64% [2] Other Notable Movements - Kuaishou-W (01024) rose over 3% as it plans to launch a live streaming initiative across multiple cities to create a collaborative ecosystem [3] - Gold stocks faced pressure, with Shandong Gold (01787) down 5.09%, China Gold International (02099) down 3.44%, Lingbao Gold (03330) down 2.68%, and Chifeng Jilong Gold (06693) down 2.33% [3] - China Shipbuilding Defense (00317) increased over 3% after the approval of a merger and acquisition restructuring plan, optimizing resources in the shipbuilding industry [3] - Medical device stocks saw a broad increase, with Spring Medical (01858) up 6.36%, Yongsheng Medical (01612) up 7.27%, Xinwei Medical-B (06609) up 3.55%, and Microneuroscience (02172) up 1.12% [3] - Some stablecoin concept stocks rose, with Victory Securities (08540) up 6.9%, Guotai Junan International (01788) up 5.15%, Yika (09923) up 2.59%, and China Everbright Holdings (00165) up 1.96% [3] - SF Express City (09699) rose nearly 7% amid intensified competition in the food delivery sector, with expectations of increased order volume [3] - HSSP International (03626) fell over 20% after being named by the Hong Kong Securities and Futures Commission for high stock concentration [3] Strategic Partnerships and New Listings - Shengye (06069) opened nearly 15% higher after forming a strategic partnership with Stand Robot to enhance its robotics industry chain [4] - Beverage stocks opened high, with Cha Bai Dao (02555) up 15%, Nayuki's Tea (02150) up 9.87%, Gu Ming (01364) up 5.77%, Hu Shang Ayi (02589) up 2.99%, and Mixue Group (02097) up 2.92% [4] - FWD Group (01828) had a flat opening on its first day of listing, being a life insurance company under Li Zeqiang's control [4]

Group 1: Breakthrough in Visual Prosthetics - Chinese scientists have developed the world's first visual prosthetic with ultra-wide spectral response capabilities, enabling blind animals to regain visible light vision and expand their visual functions [1] - The retinal prosthetic, based on tellurium nanowire networks (TeNWNs), covers a spectral range from visible light (470nm) to near-infrared (1550nm), surpassing the natural human vision range of 380-780nm [1] - This technology avoids the risks associated with invasive brain surgeries and breaks the physiological limits of human vision, allowing users to perceive infrared light and accurately locate infrared light sources [1] Group 2: Growth of Brain-Computer Interface (BCI) Market - The global brain-computer interface technology is rapidly advancing, with significant attention from tech companies, medical institutions, academic research organizations, and government departments [2] - McKinsey predicts that the BCI medical application market could reach $40 billion by 2030 and $145 billion by 2040, with serious medical applications for central nervous system diseases estimated at $15 billion in 2030 and $85 billion in 2040 [2] - The domestic BCI companies are expected to gradually achieve commercialization due to technological innovations and favorable policies promoting industry development [2] Group 3: Related Companies in the BCI Sector - Micron Brain Science (02172) is a leading company in the domestic neuro-interventional medical device field, covering hemorrhagic stroke, atherosclerosis, and acute ischemic stroke, maintaining the top position in the domestic market share [3] - Xinwei Medical-B (06609) successfully completed animal trials for China's first interventional brain-computer interface, developed in collaboration with Nankai University's AI team [3] - Nanjing Panda Electronics (00553) is involved in the development of a multimodal human-computer interaction system based on BCI technology, which has been included in Jiangsu Province's key research and development plan [3]